VALUE IN HEALTH

Caring for Carers: Positive and Normative Challenges for Future Research on Carer Spillover Effects in Economic Evaluation

PND9 EVENT-FREE SURVIVAL AND MOTOR MILESTONE ACHIEVEMENT FOLLOWING AVXS-101 AND NUSINERSEN INTERVENTIONS CONTRASTED TO NATURAL HISTORY FOR TYPE I SPINAL MUSCULAR ATROPHY PATIENTS

ECONOMIC ASSESSMENT OF A HIGH DOSE VERSUS A STANDARD DOSE INFLUENZA VACCINE IN THE US VETERAN POPULATION: ESTIMATING THE IMPACT ON HOSPITALIZATION COST FOR CARDIOVASCULAR AND RESPIRATORY DISEASE

PGI29 AN ECONOMIC EVALUATION OF TOFACITINIB IN THE TREATMENT OF MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE UNITED KINGDOM

PNS176 ECONOMIC EVALUATION OF MEDICAL DEVICES: ARE THERE LESSONS TO BE LEARNT FROM EUROPE

Where do we go with Whole Genome Sequencing in oncology? Using scenario drafting to explore future developments

PCV17 ASSOCIATION BETWEEN EXPOSURE/ADHERENCE TO A CARDIOVASCULAR RISK MANAGEMENT PROGRAM AND THE INCIDENCE AND MORTALITY OF CARDIOVASCULAR EVENTS IN THE CARIBBEAN REGION OF COLOMBIA

PMH53 IMPACT OF COGNITIVE SYMPTOMS ON HEALTH-RELATED QUALITY OF LIFE AND WORK PRODUCTIVITY IN CHINESE PATIENTS WITH MAJOR DEPRESSIVE DISORDER: RESULTS FROM THE PROACT STUDY

PIN73 THE POTENTIAL COST-EFFECTIVENESS OF QUADRIVALENT VERSUS TRIVALENT INACTIVATED INFLUENZA VACCINE FOR THE PORTUGUESE ELDERLY POPULATION

PCN168 GLOBAL BURDEN OF WALDENSTRÖM MACROGLOBULINEMIA (WM): A SYSTEMATIC LITERATURE REVIEW (SLR) AND EVIDENCE GAP ANALYSIS

PIN90 HEALTH-ECONOMIC MODELLING TO INFORM PRIVATE SECTOR INVESTMENT IN INFECTIOUS DISEASE TREATMENTS IN MIDDLE-INCOME COUNTRIES: THE CASE OF TUBERCULOSIS

PDB70 CHARACTERISTICS OF PATIENTS WITH TYPE 2 DIABETES MELLITUS NEWLY TREATED WITH BASAL INSULIN THERAPY: A POPULATION-BASED UK STUDY

PIN58 ARE PUBLISHED HEALTH ECONOMIC MODELS FOR CHRONIC HEPATITIS B APPROPRIATELY CAPTURING THE BENEFITS OF HBSAG LOSS

PCV5 PREVALENCE OF FOUR STATIN BENEFIT GROUPS IN A POPULATION OF THE CARIBBEAN REGION OF COLOMBIA

Health-economic modelling of infectious disease diagnostics: current approaches and future opportunities

PIH1 EVALUATION AND EFFECTIVENESS OF FIRST-LINE TREATMENTS FOR POLYCYSTIC OVARY SYNDROME (PCOS) ANOVULATORY INFERTILITY: A REAL WORLD EVIDENCE STUDY

PCN3 EPIDEMIOLOGICAL, CLINICAL AND HUMANISTIC BURDEN AMONG ALK+ NON-SMALL CELL LUNG CANCER (ALK+NSCLC) PATIENTS TREATED WITH FIRST-LINE ALK INHIBITORS: RESULTS OF A SYSTEMATIC LITERATURE REVIEW (SLR)

PDB34 A PERSONALIZED SCREENING STRATEGY FOR DIABETIC RETINOPATHY : A COST-EFFECTIVENESS PERSPECTIVE

PNS210 REVIEW OF CANADIAN VERSUS OTHER GUIDELINES FOR CONDUCTING BUDGET IMPACT ANALYSIS: DO CANADIAN GUIDELINES DIFFER AND WHY?

MS1 A COMPARISON OF THREE AND FOUR STATE ECONOMIC MODELS FOR COST-EFFECTIVENESS ANALYSIS IN ONCOLOGY

Switching to insulin degludec is a cost-saving therapy for patients with type 1 and type 2 diabetes in the Swedish setting based on real world data

PCN349 Value of information analysis guiding the reimbursement decision of olaparib for metastatic breast cancer

PMU31 early cost-effectiveness analysis of continuous monitoring of lung-aeration with electrical impedance tomography in preterm neonates with respiratory distress syndrome

PSY18 AN ANALYSIS OF TREATMENT PATTERNS IN KNEE OSTEOARTHRITIS IN A U.S. ADMINISTRATIVE CLAIMS DATABASE

PIN93 PREDICTION MODEL OF TREATMENT FAILURE AMONG CHRONIC HEPATITIS C PATIENTS AT FOUR UNITED STATES INSTITUTIONS

PRO53 WHAT IS THE RELATIONSHIP BETWEEN PRICE AND PREVALENCE IN NON-ONCOLOGY RARE DISEASE?

PNS63 MODELING REDUCTIONS IN ABSOLUTE CANCER MORTALITY FROM DIAGNOSING CANCERS BEFORE METASTASIS, 2006-2015

More information worse decisions? : Evaluating potential overuse of laboratory diagnostics in diagnosing anaemia

PMH49 PERSONALIZED HEALTHCARE EPISODE IDENTIFICATION IN SCHIZOPHRENIA SPECTRUM DISORDER USING HEALTHCARE CONSUMPTION TRAJECTORIES

PND75 VALIDATION OF AN ALGORITHM IDENTIFYING RELAPSES IN MULTIPLE SCLEROSIS USING THE FRENCH NATIONWIDE CLAIMS DATABASE

PND43 THE BURDEN OF PEDIATRIC PARTIAL ONSET SEIZURES: A REVIEW OF THE LITERATURE